Azar shahraz
Director - Clinical Pharmacology & Pharmacology Abbvie
Azar Shahraz is Group Director of Clinical Pharmacology at AbbVie, where she leads clinical pharmacology strategy for oncology solid tumor programs. With extensive experience spanning oncology, RNA therapeutics, pharmacometrics, PBPK modelling, and quantitative systems pharmacology, she has held leadership roles at AstraZeneca, Alnylam Pharmaceuticals, and Simulations Plus, contributing to the development and regulatory advancement of innovative therapies across multiple modalities. Her expertise spans model-informed drug development, translational science, and the application of quantitative approaches to accelerate decision-making throughout drug development.
Seminars
- The practical challenge of communicating model outputs, assumptions, and uncertainty to cross-functional colleagues and senior leaders who need to make decisions based on those outputs without a pharmacometrics background
- Frameworks for presenting model credibility to internal stakeholders, including how to communicate what the model can and cannot tell you without undermining confidence in the work
- Case examples where poor internal communication of MIDD results delayed a development decision, and what changed when the communication approach was redesigned
A moderated panel drawing on speakers from across both conference days to share honest retrospective experience of MIDD implementation.
- Where has MIDD genuinely changed a development decision, and where has it been used to validate a decision that had already been made?
- What has been the hardest internal sell for MIDD, and what argument finally worked?
- Where have you seen the field overclaim what modelling can do, and what are the consequences of that for regulatory trust?
